Ticker Details
BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
IPO Date:	August 1, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$10.83B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.86 | 1.63%
Avg Daily Range (30 D):	$0.65 | 1.13%
Avg Daily Range (90 D):	$0.80 | 1.40%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.5M
Avg Daily Volume (90 D):	1.81M

Trade Size
Avg Trade Size (Sh.):	102
Avg Trade Size (Sh.) (30 D):	56
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	24,490
Avg Institutional Trade:	$3.64M
Avg Institutional Trade (30 D):	$6.33M
Avg Institutional Trade (90 D):	$5.99M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$11.3M
Avg Closing Trade (30 D):	$21.66M
Avg Closing Trade (90 D):	$22.78M
Avg Closing Volume:	145.73K

News

Mar 20, 2026 @ 4:07 PM Biotech Stock Up 372% Gets Sold as New Pick Rises ... Source: Jonathan Ponciano

Mar 17, 2026 @ 12:00 AM This Investor Sold $104 Million of Nuvalent Stock ... Source: Jonathan Ponciano

Mar 10, 2026 @ 6:49 PM BridgeBio's Rare-Disease Pipeline Sparks Growth Bu... Source: Vandana Singh

Mar 5, 2026 @ 9:51 AM Skeletal Dysplasia Market - Global Forecast 2026-2... Source: Researchandmarkets.Com

Feb 12, 2026 @ 5:44 PM BridgeBio Nears 52-Week High On Strong Dwarfism Tr... Source: Vandana Singh

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$1.82	$-.24	$1.82
Diluted EPS	$1.8	$-.24	$1.8
Revenue	$3.22B	$874.57M	$3.22B
Gross Profit	$2.5B	$598.86M	$2.5B
Net Income / Loss	$348.9M	$-46.57M	$348.9M
Operating Income / Loss	$409.48M	$-44.61M	$409.48M
Cost of Revenue	$717.44M	$275.71M	$717.44M
Net Cash Flow	$371.36M	$60.35M	$371.36M
PE Ratio	30.31